Obese frailty, physical performance deficits, and falls in older XXXX with biochemical recurrence of @entity263 on @entity342 deprivation therapy: a case-control study.

@entity1 @entity263 @entity28 @entity342 @entity165 @entity1851
OBJECTIVES: To test the hypothesis that early @entity342 deprivation therapy (ADT) has no proven survival advantage in older @entity1 with biochemical recurrence (BCR) of @entity263 ( @entity263 ), and it may contribute to geriatric frailty. METHODS: We conducted a case-control study of @entity1 aged 60+ years with BCR on ADT (n = 63) vs @entity263 survivors without recurrence (n = 71). Frailty prevalence, " @entity28 " frailty, Short Physical Performance Battery (SPPB) scores, and falls were compared. An exploratory analysis of frailty biomarkers ( @entity1851 , erythrocyte sedimentation rate, hemoglobin, albumin, and total @entity165 ) was performed. Summary statistics and univariate and multivariate regression analyses were conducted. RESULTS: More @entity1 on ADT were @entity28 (body mass index >30; 46.2% vs 20.6%; P = .03). There were no statistical differences in SPPB (P = .41) or frailty (P = .20). Using a proposed " @entity28 " frailty criteria, 8.7% in ADT group were frail and 56.5% were "prefrail," compared with 2.9% and 48.8% of controls (P = .02). Falls in the last year were higher in the ADT group (14.3% vs 2.8%; P = .02). In analyses controlling for age, clinical characteristics, and comorbidities, the ADT group trended toward significance for " @entity28 " frailty (P = .14) and falls (OR = 4.74, P = .11). Comorbidity significantly increased the likelihood of " @entity28 " frailty (P = .01) and falls (OR 2.02, P = .01). CONCLUSIONS: @entity1 with BCR on ADT are frailer using proposed modified " @entity28 " frailty criteria. They may have lower performance status and more falls. A larger, prospective trial is necessary to establish a causal link between ADT use and progression of frailty and disability.
